WHATNEXT partner Patient Worthy recently reported on the development of an investigational therapy intended to target HER2-positive cancers. One of the most common HER2-positive cancers is breast cancer. The experimental therapy, designated CT-0508, is being developed by Carisma Therapeutics and is classified as a CAR-M therapy.
Author Rose Duesterald states:
CT-0508 is defined as a human epidermal growth factor receptor 2 (HER2) targeted CAR-Macrophage. In 2021, the FDA granted fast track designation to HER2-directed CAR macrophage (CAR-M) CT-0508 for use as a possible therapeutic option.
Prior studies of CAR-M therapies highlighted its ability to penetrate the tumor and kill cancer cells. CAR-M is a therapy that extracts blood, specifically monocytes, from the patient.
The monocytes are engineered and reinfused into the patient. Notably, cytokine-related side effects have occurred after the procedure, involving the rapid release of cytokines (substances of the immune system). The symptoms that have been reported include, but are not limited to, high fever, chills, headaches, joint pain, and breathing difficulties.
Check out the full story here.
Editor’s Note: Get Involved
Cancer doesn’t discriminate. Patient Worthy and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have a cancer journey to share, reach out here to learn more about how your voice can help spread awareness and inspire individuals from all walks of life.
breast cancer HER2 positive cancer HER2+ breast cancer HER2+ cancer research
Last modified: April 1, 2024
